A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer.
Level 5 - mechanism / opinion, no new human data
Preclinical mechanistic bench research evaluating molecular pathways and enzyme mutations.
PubMed 23993097 · doi:10.1016/j.cell.2013.07.029
What was done
The authors investigated molecular mechanisms of androgen synthesis in castration-resistant prostate cancer (CRPC). They evaluated the functional consequences of an N367T missense mutation in 3β-hydroxysteroid dehydrogenase type 1 (3βHSD1), the enzyme catalyzing the initial rate-limiting step in converting adrenal-derived dehydroepiandrosterone (DHEA) to dihydrotestosterone (DHT).
What was found
The N367T mutation in 3βHSD1 did not alter baseline catalytic function but conferred resistance to ubiquitination and proteasomal degradation, resulting in enzyme accumulation. Expression of the stabilized 367T variant accelerated the conversion of DHEA into DHT, providing sufficient ligand to activate the androgen receptor. The abstract provides no quantitative measurements, effect sizes, or statistical values.
Why it matters
This study identifies a post-translational stabilization mechanism allowing prostate cancer cells to bypass androgen deprivation therapy by hyper-converting adrenal precursor steroids into DHT, establishing 3βHSD1 as a potential therapeutic target in CRPC.
Limits
The abstract reports purely preclinical mechanistic laboratory findings without human clinical outcomes, sample sizes, or quantitative data. The exact prevalence of this mutation in clinical CRPC cohorts and the in vivo efficacy of targeting 3βHSD1 are not reported in the abstract.
Cited by
- supports Dihydrotestosterone (DHT) is the most potent androgenic hormone in the human body.